SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the Nasdaq 20th Investor Program
in London on Thursday, December 6, 2007 at 7:15 a.m. PT / 3:15 p.m. GMT
local time in the UK. Berthold Lensker, Ph.D., Executive Director of
European Operations, will be providing a corporate overview of Amylin
Pharmaceuticals.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Amylin's corporate website, located at http://www.amylin.com. To
access the live webcast, please log on to Amylin's site approximately
fifteen minutes prior to the presentation to register and download any
necessary audio software.
More information about the Nasdaq 20th Investor Program is available
at: http://december.nasdaqconference.com/info.asp.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,800 employees nationwide.
Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
http://december.nasdaqconference.com/info.asp
CONTACT:
Alice Bahner Izzo, Executive Director,
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, ext. 7272
|
